Key Takeaways
AnaptysBio Inc. (Nasdaq: ANAB) completed the spin-off of its biopharma business on April 20, creating a royalty management company with a projected EBIT margin over 95 percent.
"This structure positions us to operate without complexity and deliver maximum value to shareholders,” Daniel Faga, president and chief executive officer of AnaptysBio, said in a statement.
The new entity, First Tracks Biotherapeutics Inc., began trading today on the Nasdaq Global Select Market under the ticker symbol “TRAX”. AnaptysBio will continue to trade as “ANAB” and will manage royalties from its out-licensed assets, Jemperli with GSK and imsidolimab with Vanda.
The move transforms AnaptysBio from a clinical-stage biotech into a streamlined financial company, a shift intended to attract investors focused on value and income. Shareholders received one share of TRAX for every ANAB share held as of the April 6 record date.
The restructuring simplifies AnaptysBio's business model to focus on high-margin royalty streams with minimal operating expenses. Investors will now assess two distinct companies: a pure-play royalty manager in AnaptysBio and a development-stage immunology company in First Tracks Biotherapeutics. The market's valuation of both ANAB and TRAX in the coming weeks will signal its verdict on the separation.
This article is for informational purposes only and does not constitute investment advice.
